Bernard C. Rudnick, Founder and Managing Partner of CapGenic Advisors LLC
Mr. Rudnick is Founder and Managing Partner of CapGenic Advisors, LLC, CEO of Virion Therapeutics and a member of several angel groups. Mr. Rudnick’s entrepreneurial career includes a number of startups, three of which resulted in significant investor return upon exit. He is a founder of one of the nation’s leading entrepreneurial programs (MADV) at the Fox School of Business, a director of PainQx, Atrin Pharmaceuticals, Axxia Pharmaceuticals, Virion Therapeutics, SageMedic, Operative Experience and former director and CFO of Immunomic Therapeutics.
With 36 years of experience in executive-level strategy, finance, and management, Mr. Rudnick has senior merger, acquisition, capital formation and licensing leadership experience with companies ranging from start-up to Fortune 50. He has substantial experience investing and guiding investments in entrepreneurial companies and has led capital formation and merger transactions totaling in the billions.
Mr. Rudnick currently advises companies in the clinical software, therapeutic, and medical device areas. His advisory clients have included Mitsui (Mitrix), DuPont (Agri-chemical), McKesson Bioservices (now TMO), Kika Clinical Solutions (now IBM) as well as a number of early stage life sciences companies. Angel group affiliations include Minority Angel Investment Network, a founder of Mid-Atlantic Bio Angel, a member of Keiretsu Mid-Atlantic and Robin Hood Ventures. He is a limited partner in four venture funds and serves in the investment committee of two. Not-for-profit board affiliations include Penn State Medical School and Temple University technology commercialization boards, and advisory to UPstart program at the University of Pennsylvania.